Navigation Links
Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
Date:11/29/2007

Mechelen, Belgium and Bethesda, Maryland, USA; 29 November 2007 Galapagos NV (Euronext & LSE: GLPG) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the non-profit affiliate of the Cystic Fibrosis Foundation, announced today a new collaboration aimed at discovering new treatments for cystic fibrosis. This new agreement between CFFT and Galapagos BioFocus DPI service division is worth up to 5.5 million euros ($8.1 million U.S. dollars) for Galapagos.

The collaboration will combine two key strengths of BioFocus DPI expertise in natural product drug discovery and screening in cells derived from patients. Specifically, the collaboration aims to identify small molecules derived from natural sources that improve the function of a defective protein found in people who have cystic fibrosis. The protein is called CFTR - cystic fibrosis transmembrane conductance regulator. To advance the search for a cure for cystic fibrosis, CFFT funds promising scientific research in the pharmaceutical and biotechnology industry and academia worldwide.

Under the terms of the agreement, Galapagos stands to receive up to 1.6 million ($2.4 million) in upfront and research fees over the next two years, and up to 3.8 million ($5.7 million) in success-based milestone payments, should certain clinical development criteria be met.

This drug discovery collaboration is in addition to an ongoing target discovery program established between CFFT and BioFocus DPI in April 2005.

We are excited to take advantage of the innovative drug discovery approach developed by BioFocus DPI and the companys extensive expertise in natural compounds, said Robert J. Beall, Ph.D., President and CEO of the Cystic Fibrosis Foundation. By exploring compounds derived from natural sources, our goal is to increase the number and diversity of drug candidates in development to treat cystic fibrosis.

The CFFT drug discovery collaboration is a prime example of the kind of innovation we aimed to achieve through our acquisition strategy, said Onno van de Stolpe, CEO of Galapagos. We have seen a growing interest in natural product based drug discovery since acquiring these capabilities last year. By combining this expertise with our know-how in cell-based screening, we are confident that we will contribute to the advancement of CFFTs drug discovery program in novel ways.


'/>"/>

Contact: Lily Mccutchan
lmccutchan@cff.org
301-841-2674
Cystic Fibrosis Foundation
Source:Eurekalert

Related biology news :

1. Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials
2. Balzan Foundation announces 2007 winners
3. Keck Foundation funds study of biological interactions with nanomaterials
4. Yu receives research funding from the Wallace H. Coulter Foundation
5. PETA awards $120,000 to Duluth Foundation for advancing non-animal tests
6. Simons Foundation awards Emory scientists $3M for autism gene research
7. Arizona State University launches biofuel initiative with BP and Science Foundation Arizona
8. Life-saving clean water project secures $13M from Bill & Melinda Gates Foundation
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. LaserCard Corporation Announces Expansion of Middle East Project
11. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2018)... Kan. (PRWEB) , ... October 18, 2018 , ... ... 23andMe, Inc., a leader among services that offer direct-to-consumer DNA Testing for health ... seems to be everywhere. The reasons are many: some people want to find ...
(Date:10/18/2018)... ... October 18, 2018 , ... On June 11 of this year, ... of gene-editing therapeutics to hold its collective breath. Two different research teams independently ... of p53 gene mutation. Mutations in the p53 gene have the distinction of ...
(Date:10/18/2018)... STATION, Texas (PRWEB) , ... October 18, 2018 ... ... step closer to reality , Texas A&M receives USDA-APHIS deregulation approval , Writer: ... into flour to deliver protein to millions of people, a project to which ...
Breaking Biology News(10 mins):
(Date:10/17/2018)... ... 2018 , ... Dr. Richard Amato, founder of Advanced Periodontics ... offering current and new patients the opportunity to enjoy improved tooth extraction, bone ... technology known as Piezosurgery® . As long-time believers in staying ahead of ...
(Date:10/16/2018)... N.J. (PRWEB) , ... October 15, 2018 , ... ... have characterized tissues through the visualization of histopathology slides by eye wherein key ... the gold standard for diagnosis and research, it is highly limited in that ...
(Date:10/11/2018)... ... October 11, 2018 , ... Avery Products ... solutions, in collaboration with HP, the global leader in printing, has obtained the ... Labels on all HP PageWide Printers. , The award-winning Avery UltraDuty GHS Chemical ...
(Date:10/3/2018)... Conn. (PRWEB) , ... October 03, 2018 , ... Milwaukee ... public open house Wednesday, Oct. 17, from 3-7 p.m. in Room T129 in the ... leaders to its new CNC Swiss Lab. A ribbon cutting and formal program will ...
Breaking Biology Technology: